Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 702Terminated 227Recruiting 146Active not recruiting 129Unknown 112Withdrawn 55Not yet recruiting 23Suspended 5Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER 3OTHER_GOV 1NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 2Recurrence 1Lymphoma 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 8Vincristine 7Prednisone 6Specimen Handling 5Rituximab 5Doxorubicin 5zanubrutinib 3prednylidene 3deltacortene 3Magnetic Resonance Spectroscopy 3tazemetostat 2fludarabine phosphate 2fludarabine 2Radiotherapy, Intensity-Modulated 2Melphalan 2Etoposide 2Drug Therapy 2CT-P10 2Biopsy 2Azacitidine 2Antibodies, Monoclonal 2vactosertib 1tisagenlecleucel 1sargramostim 1ponatinib 1pembrolizumab 1obinutuzumab 1mogamulizumab 1glucarpidase 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Suspended × Rituximab × Lymphoid × Clear all
NCT06824701 2026-04-06

TARZAN

University of Utah

Phase 1 Suspended
24 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT04850495 2026-02-06

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Suspended
38 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Henan Cancer Hospital

Phase 2 Suspended
59 enrolled
Lymphoid

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

NCT03704714 2022-08-15

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Northwestern University

Phase 1/2 Suspended
30 enrolled
Lymphoid

Lymphoma, B-Cell

NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡